Cited by 1,226Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAging, Health, and Disability

The DOI matches its Crossref record.

Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported

Evans, Denis A.·1989·JAMA

DOI 10.1001/jama.1989.03430180093036

Open this paper in CoChat — free account

Abstract

Clinically diagnosed Alzheimer's disease and other dementing illnesses were assessed in a geographically defined US community. Of 3623 persons (80.8% of all community residents over 65 years of age) who had brief memory testing in their homes, a stratified sample of 467 persons underwent neurological, neuropsychological, and laboratory examination. Prevalence rates of Alzheimer's disease were calculated for the community population from the sample undergoing clinical evaluation. Of those over the age of 65 years, an estimated 10.3% (95% confidence limits, 8.1% and 12.5%) had probable Alzheimer's disease. This prevalence rate was strongly associated with age. Of those 65 to 74 years old, 3.0% (95% confidence limits, 0.8 and 5.2) had probable Alzheimer's disease, compared with 18.7% (95% confidence limits, 13.2 and 24.2) of those 75 to 84 years old and 47.2% (95% confidence limits, 37.0 and 63.2) of those over 85 years. Other dementing conditions were uncommon. Of community residents with moderate or severe cognitive impairment, 84.1% had clinically diagnosed Alzheimer's disease as the only probable diagnosis. These data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population. (JAMA. 1989;262:2551-2556)

Integrity signals

Registry

Crossref · 10.1001/jama.1989.03430180093036

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92338-8 · Cited by 1,267
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
“Atypical cases of AD (see description above) can closely resemble FTD spectrum disorders (primary progressive aphasia [PPA], bvFTD), and in these cases MRI and AD biomarker studies (e.g., amyloid-PET, CSF Ab1-42 amyloid, t-tau, and p-tau) can help distinguish the two diagnostic entities.”
BackgroundInfluential
The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education
Zhang, M., Katzman, R., Salmon, D. P., Jin, H., Cai, G., Wang, Z., Qu, G.-Y., Grant, I., Yu, E. S. H., Levy, P. S., et al. (1990) · Annals of Neurology · doi:10.1002/ana.410270412 · Cited by 1,068
Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease
Mecocci, P., MacGarvey, U., & Beal, M. F. (1994) · Annals of Neurology · doi:10.1002/ana.410360510 · Cited by 1,037
Prevalence and severity of cognitive impairment with and without dementia in an elderly population
Graham, J., Rockwood, K. J., Beattie, B. L., Eastwood, R., Gauthier, S. G., Tuokko, H. A., & McDowell, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01007-6 · Cited by 1,017
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age
Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., Flint Beal, M., & Wallace, D. C. (1992) · Nature Genetics · doi:10.1038/ng1292-324 · Cited by 890
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 892
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy‐Lahad, E., Wijsman, E. M., Nemens, E. J., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 832
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758
Comparison of the Saint Louis university mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study
Tariq, S. H., Tumosa, N., Chibnall, J. T., Perry, M. H., & Morley, J. E. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221510.33817.86 · Cited by 724
Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan
Tang, M. ‐., Cross, P. S., Andrews, H., Jacobs, D. M., Small, S. A., Bell, K., Merchant, C., Lantigua, R., Costa, R., Stern, Y., et al. (2001) · Neurology · doi:10.1212/wnl.56.1.49 · Cited by 721
Cognitive impairment in hemodialysis patients is common
Murray, A. M., Tupper, D. E., Knopman, D. S., Gilbertson, D. T., Pederson, S. L., Li, S., Smith, G. E., Hochhalter, A. K., Collins, A. J., & Kane, R. L. (2006) · Neurology · doi:10.1212/01.wnl.0000225182.15532.40 · Cited by 712
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
Mitochondrial dysfunction in neurodegenerative diseases
Beal, M. F. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00114-5 · Cited by 611
Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Mosconi, L., Pupi, A., & de Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 616
Cognitive Disorders and Dementia in CKD
Bugnicourt, J., Godefroy, O., Chillon, J., Choukroun, G. J., & Massy, Z. A. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050536 · Cited by 634
Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force
Boustani, M. A., Peterson, B., Hanson, L. C., Harris, R., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00015 · Cited by 582
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El‐Agnaf, O. M. A., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 567
Ectopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain
Busser, J., Geldmacher, D. S., & Herrup, K. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02801.1998 · Cited by 543
“The prevalence of the disease increases with age, from ;1% at age 60 to nearly 50% by age 85 (Evans et al., 1989).”
Background
d -β-Hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease
Kashiwaya, Y., Takeshima, T., Mori, N., Nakashima, K., Clarke, K., & Veech, R. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5440 · Cited by 534
Nicotinic acetylcholine receptors: from structure to brain function
Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Springer eBooks · doi:10.1007/s10254-003-0005-1 · Cited by 536
Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
Hsiao, K., Borchelt, D., Olson, K., Johannsdottir, R., Kitt, C. A., Yunis, W. S., Xu, S., Eckman, C., Younkin, S. G., Price, D., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90107-8 · Cited by 527
Fatty acid analysis of blood plasma of patients with alzheimer's disease, other types of dementia, and cognitive impairment
Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., & Fisher, R. H. (2000) · Lipids · doi:10.1007/s11745-000-0646-3 · Cited by 536
“The incidence of dementia in Western countries, of which AD is the leading cause, is estimated to be approximately 10% of the population over the age of 65 y and 47% of the population over 80 y of age ( 1 ).”
Background
High, usual and impaired functioning in community-dwelling older men and women: Findings from the MacArthur Foundation Research Network on successful aging
Berkman, L. F., Seeman, T. E., Albert, M., Blazer, D. G., Kahn, R. L., Mohs, R. C., Finch, C. E., Schneider, E. L., Cotman, C. W., McClearn, G. E., et al. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90112-e · Cited by 499
Use of Brief Cognitive Tests to Identify Individuals in the Community with Clinically Diagnosed Alzheimer's Disease
Albert, M., Smith, L. A., Scherr, P. A., Taylor, J. O., Evans, D. A., & Funkenstein, H. H. (1991) · International Journal of Neuroscience · doi:10.3109/00207459109150691 · Cited by 496
Self-citation
Neurodegenerative Diseases
(1994) · Toxicology and Industrial Health · doi:10.1177/074823379401000603 · Cited by 501
GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
“Alzheimer’s disease (AD) afflicts about 10% of persons over 65 and almost half of those over 85 (Evans et al., 1989) and the number of afflicted persons continues to grow.”
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation
Quinn, P. M. J., Moreira, P. I., Ambrósio, A. F., & Alves, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01062-w · Cited by 503
“Ageing is the predominant risk factor with a prevalence of 10% for individuals over the age of 65 [114].”
Background
Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans
Hendrie, H. C., Osuntokun, B. O., Hall, K. S., Ogunniyi, A. O., Hui, S. L., Unverzagt, F. W., Gureje, O., Rodenberg, C. A., Baiyewu, O., & Musick, B. S. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1485 · Cited by 457
The Association Between Age and Health Literacy Among Elderly Persons
Baker, D. W., Gazmararian, J. A., Sudano, J. J., & Patterson, M. B. (2000) · The Journals of Gerontology Series B · doi:10.1093/geronb/55.6.s368 · Cited by 464
“The incidence and prevalence of dementia increases dramatically in those older than age 65 (Evans et al., 1989; Graham et al., 1997).”
Background
Adaptación y validación al castellano del cuestionario de Pfeiffer (SPMSQ) para detectar la existencia de deterioro cognitivo en personas mayores e 65 años
de la Iglesiaa, J. M., DueñasHerrerob, R., Vilchesa, M. C. O., Tabernéa, C. A., Colomerc, C. A., & Luque, R. (2001) · Medicina Clínica · doi:10.1016/s0025-7753(01)72040-4 · Cited by 461
Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies
Vemuri, P., Gunter, J. L., Senjem, M. L., Whitwell, J. L., Kantarci, K., Knopman, D. S., Boeve, B. F., Petersen, R. C., & Jack, C. R. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.073 · Cited by 465
“Based on the estimates in Evans et al. (1989), an average of 18.7% and 47.2% of the general population at an age of 75–85 years and N85 years, respectively, have AD.”
BackgroundInfluential
Substituted Judgment: How Accurate Are Proxy Predictions?
Seckler, A. B., Meier, D. E., Mulvihill, M., & Paris, B. E. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-2-92 · Cited by 455
Dementia caregiver burden
Dunkin, J. J., & Anderson‐Hanley, C. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s53 · Cited by 439
Dietary factors and Alzheimer's disease
Luchsinger, J. A., & Mayeux, R. P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00878-6 · Cited by 442
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease
De Leon, M. J., George, A. E., Golomb, J., Tarshish, C., Convit, A., Kluger, A., De Santi, S., Mc Rae, T., Ferris, S. H., Reisberg, B., et al. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00213-8 · Cited by 429
The relationship between a dementia diagnosis, chronic illness, Medicare expenditures, and hospital use
Bynum, J. P. W., Rabins, P. V., Weller, W., Niefeld, M., Anderson, G. F., & Wu, A. W. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52054.x · Cited by 405
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders
Howes, M. R., Perry, N. S. L., & Houghton, P. J. (2003) · Phytotherapy Research · doi:10.1002/ptr.1280 · Cited by 421
Confidence intervals for predictive values with an emphasis to case–control studies
Mercaldo, N. D., Lau, K. F., & Zhou, X. (2006) · Statistics in Medicine · doi:10.1002/sim.2677 · Cited by 426
Epidemiology of Dementia and Alzheimer's Disease
Hendrie, H. C. (1998) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00002 · Cited by 411
A normative study of the CERAD neuropsychological assessment battery in the Korean elderly
LEE, D. Y., Lee, K. U., Lee, H., Kim, K. W., Jhoo, J. H., Kim, S. Y., Yoon, J. C., WOO, S. I., Ha, J. B., & Woo, J. I. (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704101094 · Cited by 413
“The prevalence rate of dementia is approximately 8.2–9.5% in Korea (D. Lee et al., 2002; Woo et al., 1998) and 6.3–10.3% in Western countries (Canadian Study of Health and Aging Working Group, 1994; Evans et al., 1989; Livingston et al., 1990).”
BackgroundInfluential
National estimates of the prevalence of Alzheimer's disease in the United States
Brookmeyer, R., Evans, D. A., Hebert, L. E., Langa, K. M., Heeringa, S. G., Plassman, B. L., & Kukull, W. A. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.11.007 · Cited by 416
Self-citation
Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388
Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer's disease animal model
Yue, X., Lu, M. G. W., Lancaster, T., Cao, P., Honda, S., Staufenbiel, M., Harada, N., Zhong, Z., Shen, Y., & Li, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505203102 · Cited by 404
Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980–1990 prevalence findings
Rocca, W. A., Albert Hofman, D., Brayne, C., Breteler, M. M. B., Clarke, M., Copeland, J. R. M., Dartigues, J., Engedal, K., Hagnell, O., Heeren, T. J., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410300310 · Cited by 384
Implementing a screening and diagnosis program for dementia in primary care
Boustani, M., Callahan, C. M., Unverzagt, F. W., Austrom, M. G., Perkins, A. J., Fultz, B. A., Hui, S. L., & Hendrie, H. C. (2005) · Journal of General Internal Medicine · doi:10.1007/s11606-005-0103-7 · Cited by 374
ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia
Jeste, D. V., Blazer, D. G., Casey, D. E., Meeks, T. W., Salzman, C., Schneider, L. S. S., Tariot, P. N., & Yaffe, K. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301492 · Cited by 429
“Among US adults over age 65, prevalence estimates of dementia range from 5 to 15%, with Alzheimer’s Disease (AD) being the most common type of dementia (Kaplan and Sadock, 1998; Evans et al, 1989; Losonczy et al, 1998).”
Background
Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids
Harris, W. S., Mozaffarian, D., Lefevre, M., Toner, C. D., Colombo, J., Cunnane, S. C., Holden, J. M., Klurfeld, D. M., Morris, M. C., & Whelan, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.101329 · Cited by 356
Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases
Fiskum, G. M., Murphy, A. N., & Beal, M. F. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199904000-00001 · Cited by 354
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial
Akhondzadeh, S., Noroozıan, M., Mohammadi, M., Ohadinia, S., Jamshidi, A. H., & Khani, M. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00463.x · Cited by 345
“It is the most common form of dementia, affecting approximately 20 million people worldwide (1, 2).”
Background
Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism
Takikawa, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.032 · Cited by 344
Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R., & White, L. R. (2000) · Neurology · doi:10.1212/wnl.54.6.1265 · Cited by 330
Established populations for epidemiologic studies of the elderly: Study design and methodology
Cornoni‐Huntley, J. C., Ostfeld, A. M., Taylor, J. O., Wallace, R. B., Blazer, D. G., Berkman, L. F., Evans, D. A., Kohout, J., Lemke, J. H., Scherr, P. A., et al. (1993) · Aging Clinical and Experimental Research · doi:10.1007/bf03324123 · Cited by 326
Self-citation
The Women’s Health Initiative Memory Study (WHIMS)
Shumaker, S. A., Reboussin, B. A., Espeland, M. A., Rapp, S. R., McBee, W. L., Dailey, M., Bowen, D. J., Terrell, T., & Jones, B. N. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00038-5 · Cited by 321
Prevalence of biologically vs clinically defined alzheimer spectrum entities using the National Institute on Aging–Alzheimer's Association Research Framework
Jack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300
Diagnosis of Cerebral Amyloid Angiopathy: Sensitivity and Specificity of Cortical Biopsy
Greenberg, S. M., & Vonsattel, J.-P. G. (1997) · Stroke · doi:10.1161/01.str.28.7.1418 · Cited by 312
Provisional Diagnostic Criteria for Depression of Alzheimer Disease: Rationale and Background
Olin, J. T., Katz, I. R., Meyers, B. S., Schneider, L. S. S., & Lebowitz, B. D. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200203000-00004 · Cited by 321
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
Van der Auwera, I., Wera, S., Van Leuven, F., & Henderson, S. T. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-28 · Cited by 307
“Background Alzheimer's disease (AD) is an age-associated neurodegenerative disease that is very common in the US, affecting up to 50% of people between the ages of 75 to 84 years [1].”
Background
Brain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306
“One in every eight persons over 65 is estimated to have AD, 40 – 50% past the age of 85 may have it, and in some very elderly sub-groups the ﬁ gure appears to surpass 50% [2,6 – 8].”
Background
Achieving and Maintaining Cognitive Vitality With Aging
Fillit, H. M., Butler, R. N., O’Connell, A. W., Albert, M., Birren, J. E., Cotman, C. W., Greenough, W. T., Gold, P. E., Kramer, A. F., Kuller, L. H., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.681 · Cited by 304
Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old?
Lautenschlager, N. T., Cupples, L. A., Rao, V. S., Auerbach, S. A., Becker, R., Burke, J., Chui, H., Duara, R., Foley, E. J., Glatt, S. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.641 · Cited by 298
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Beal, M. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_16 · Cited by 298
When Is an Elder Old? Effect of Preexisting Conditions on Mortality in Geriatric Trauma
Grossman, M. D., Miller, D. L., Scaff, D. W., et al. (2002) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-200202000-00007 · Cited by 298
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease
Kang, D. E., Saitoh, T., Chen, X., Xia, Y., Masliah, E., Hansen, L. A., Thomas, R. G., Thal, L. J., & Katzman, R. (1997) · Neurology · doi:10.1212/wnl.49.1.56 · Cited by 211
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296
Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease
Rosario, E. R., Chang, L., Head, E. H., Stanczyk, F. Z., & Pike, C. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.008 · Cited by 289
“Introduction Advancing age is the most significant risk factor for the evelopment of Alzheimer’s disease (AD) (Evans et al., 1989; orm et al., 1987; Rocca et al., 1986).”
Background
Whole Transcriptome Sequencing Reveals Gene Expression and Splicing Differences in Brain Regions Affected by Alzheimer's Disease
Twine, N. A., Janitz, K., Wilkins, M. R., & Janitz, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016266 · Cited by 309
“Alzheimer’s disease (AD) is the most common cause of dementia in the human population; it mainly affects individuals over the age of 60, and one’s risk of developing it increases steadily with age [1].”
Background
Interventions to reduce the burden of caregiving for an adult with dementia: A meta‐analysis§
Acton, G. J., & Kang, J.-H. (2001) · Research in Nursing & Health · doi:10.1002/nur.1036 · Cited by 283
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285
“Nearly half of persons 85 years and older have late onset AD [2] and the prevalence worldwide will quadruple by mid-century [3].”
Drivers of age‐related inflammation and strategies for healthspan extension
Goldberg, E. L., & Dixit, V. D. (2015) · Immunological Reviews · doi:10.1111/imr.12295 · Cited by 274
“Alzheimer’s disease (AD) is the leading cause of dementia and its single greatest risk factor is age (44).”
Background
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
Survival of Outpatients with Alzheimer-type Dementia
Walsh, J. S. A., Welch, H. G., & Larson, E. B. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-6-429 · Cited by 267
Clock-drawing: is it the ideal cognitive screening test?
Shulman, K. I. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200006)15:6 · Cited by 1,354
Gender, sex steroid hormones, and Alzheimer’s disease
Vest, R. S., & Pike, C. J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.04.006 · Cited by 260
Variations in case definition affect prevalence but not outcomes of mild cognitive impairment
Fisk, J. D., Merry, H. R., & Rockwood, K. J. (2003) · Neurology · doi:10.1212/01.wnl.0000089238.07771.c7 · Cited by 258
Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models
Price, D. L., Sisodia, S. S., & Borchelt, D. (1998) · Science · doi:10.1126/science.282.5391.1079 · Cited by 258
Sex-differences in age-related cognitive decline in C57BL/6J mice associated with increased brain microtubule-associated protein 2 and synaptophysin immunoreactivity
Benice, T. S., Rizk, A., Kohama, S., Pfankuch, T., & Raber, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.029 · Cited by 263
Effect of Education on the Mini‐Mental State Examination as a Screening Test for Dementia
Uhlmann, R. F., & Larson, E. B. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb04454.x · Cited by 252
Genome-wide association study of Alzheimer's disease
Kamboh, M. I., Demirci, F. Y., Wang, X., Minster, R. L., Carrasquillo, M. M., Pankratz, V. S., Younkin, S. G., Saykin, A. J., Initiative, A. D. N., Jun, G., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.45 · Cited by 242
Oxidative damage in mild cognitive impairment and early Alzheimer's disease
Lovell, M. A., & Markesbery, W. R. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21346 · Cited by 249
Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia
Knopman, D. S., Boeve, B. F., & Petersen, R. C. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.10.1290 · Cited by 257
Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor
Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., & Yamanishi, Y. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.7 · Cited by 240
Questionable Dementia: Clinical Course and Predictors of Outcome
Devanand, D. P., Folz, M., Gorlyn, M., Moeller, J. R., & Stern, Y. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb00947.x · Cited by 240
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Free radical oxidation of brain proteins in accelerated senescence and its modulation by N -tert-butyl-α-phenylnitrone
Butterfield, D. A., Howard, B. J., Yatin, S. M., Allen, K. L., & Carney, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.674 · Cited by 231
Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly
Kluger, A., Ferris, S. H., Golomb, J., Mittelman, M. S., & Reisberg, B. (1999) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879901200402 · Cited by 227
Sleep Complaints in Community‐Living Older Persons: A Multifactorial Geriatric Syndrome
Fragoso, C. A. V., & Gill, T. M. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01399.x · Cited by 226
Statins for the treatment of dementia
McGuinness, B., Craig, D., Bullock, R. A., Malouf, R. S., & Passmore, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub3 · Cited by 236
Amyloid-β peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity
Hung, L. W., Ciccotosto, G. D., Giannakis, E., Tew, D. J., Perez, K., Masters, C. L., Cappai, R., Wade, J. D., & Barnham, K. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3916-08.2008 · Cited by 210
“Alzheimer’s disease (AD) is a degenerative brain disorder that accounts for 50 –70% of late-onset dementia (Evans et al., 1989).”
Background
Epidemiology of late-life mental disorders
Hybels, C. F., & Blazer, D. G. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00042-9 · Cited by 210
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Martin, L. J. (2010) · Pharmaceuticals · doi:10.3390/ph3040839 · Cited by 213
Brain Imaging of Nicotinic Receptors in Alzheimer's Disease
Wu, J., Ishikawa, M., Zhang, J., & Hashimoto, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548913 · Cited by 211
“Several reports indicated that it is affecting almost 1 in 10 individuals over the age of 65 [1], and as life expectancy increases, over 37 million people suffer with AD, and it is projected to quadruple by 2050 [2].”
Background
The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old
Barkhof, F., Polvikoski, T. M., van Straaten, E. C. W., Kalaria, R. N., Sulkava, R., Aronen, H. J., Niinistö, L., Rastas, S., Oinas, M., Scheltens, P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277459.83543.99 · Cited by 204
Folic Acid Supplementation Mitigates Alzheimer’s Disease by Reducing Inflammation: A Randomized Controlled Trial
Chen, H., Liu, S., Ji, L., Wu, T., Ji, Y., Zhou, Y., Zheng, M., Zhang, M., Xu, W., & Huang, G. (2016) · Mediators of Inflammation · doi:10.1155/2016/5912146 · Cited by 202
Spermidine and spermine delay brain aging by inducing autophagy in SAMP8 mice
Xu, T., Li, H., Dai, Z., Lau, G. K., Li, B., Zhu, W., Liu, X.-Q., Liu, H.-F., Cai, W.-W., Huang, S., et al. (2020) · Aging · doi:10.18632/aging.103035 · Cited by 210
“3% in 2030 [6], and about 1 % people suffering from dementia at the age of 60 [7].”
Background

Authors: Evans, D. A.
Corresponding author: Evans, Denis A.
ORCID: Evans, Denis A.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1989-11-10
Volume: 262
Issue: 18
Pages: 2551
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1989.03430180093036
OpenAlex: W2129678592
Cited by: 1,226
References: 0
Citations by year: 2026: 6 · 2025: 11 · 2024: 13 · 2023: 15 · 2022: 9 · 2021: 20 · 2020: 22 · 2019: 17 · 2018: 20 · 2017: 18 · 2016: 28 · 2015: 23 · 2014: 17 · 2013: 32 · 2012: 25
FWCI: 44.57
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Funders: National Institute on Aging (N01-AG02107, N01‐AG‐1‐2106, AG 06789)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Aging, Health, and Disability
Keywords: Alzheimer's disease, prevalence, older adults, dementia, age-related cognitive decline, community-dwelling older adults, cognitive impairment, age differences in prevalence, public health impact

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks